Decreasing Systemic Toxicity Via Transdermal Delivery of Anticancer Drugs

Author(s): Jia-You Fang, Pei-Feng Liu, Chun-Ming Huang

Journal Name: Current Drug Metabolism

Volume 9 , Issue 7 , 2008

Become EABM
Become Reviewer


When used at a high dose, many anticancer drugs produce undesirable side effects including hepatotoxicity. Transdermal delivery bypasses first-pass metabolism, allowing the use of a lower dose of drug while decreasing systemic toxicity. In this review, we summarize various advanced technologies for improving anticancer drug delivery via the skin. This technology is discussed in the context of three anticancer drugs, 5-fluorouracil (5-FU), methotrexate (MTX) and 5-aminolevulinic acid (5-ALA). The use of a erbium:YAG (Er:YAG) laser for transdermal delivery of anticancer drugs is specifically highlighted in this review.

Keywords: Toxicity, transdermal delivery, laser, anticancer drugs

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [592 - 597]
Pages: 6
DOI: 10.2174/138920008785821693
Price: $65

Article Metrics

PDF: 9